Results 261 to 270 of about 19,188,680 (306)

Laparoscopic ureterolithotomy: minimally invasive second line treatment

International Urology and Nephrology, 2010
To describe our experience of 33 laparoscopic ureterolithotomies for large ureteral stones.Since February 2004, in our department, 33 patients had undergone laparoscopic ureterolithotomy. Inclusion criteria were failure of SWL and\or ureteroscopic treatment. Stones were located in the lower ureter in 9 patients, in the mid ureter in 16 patients, and in
Simone G, LEONARDO, Costantino, Papalia R, Guaglianone S, Ferriero M, Gallucci M.   +5 more
openaire   +4 more sources

Second-Line Switch to Dolutegravir for Treatment of HIV Infection

New England Journal of Medicine, 2023
Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype information and who have viral suppression with second-line therapy containing a ritonavir-boosted PI have been limited.In a prospective, multicenter, open-label trial ...
Loice A. Ombajo, Jeremy Penner, Joseph Nkuranga, Jared Mecha, Margaret Mburu, Collins Odhiambo, Florentius Ndinya, Rukia Aksam, Richard Njenga, Simon Wahome, Peter Muiruri, Sheila Eshiwani, Maureen Kimani, Catherine Ngugi, Anton Pozniak   +14 more
openaire   +2 more sources

Second-line treatment of metastatic prostatic carcinoma

Urological Research, 1997
Second-line palliative treatment of patients who have failed hormone therapy for advanced prostate cancer remains an important challenge in this disease. Very few agents have been shown to have a positive impact on survival, and toxicity is often therapy limiting in this elderly group of patients.
openaire   +2 more sources

Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma

Oncology, 2020
<b><i>Introduction:</i></b> Carcinosarcoma is a rare cancer, and its prognosis is poor. There are few reports on the prognostic factors of patients with carcinosarcoma who receive second-line chemotherapy. <b><i>Objective:</i></b> To investigate the outcome and prognostic factors of patients who received ...
Takahiro Ebata, Kan Yonemori, Tadaaki Nishikawa, Kazuki Sudo, Akihiko Shimomura, Emi Noguchi, Yasuhiro Fujiwara, Tomoyasu Kato, Kosei Hasegawa, Keiichi Fujiwara, Kenji Tamura   +10 more
openaire   +2 more sources

Should   blockers be second line treatment?

BMJ, 2010
Boger-Megiddo and colleagues’ article implies that β blockers are a better second line agent for management of hypertension than calcium channel blockers,1 but we disagree. After myocardial infarction, β blockade, but not calcium channel blockade, confers prognostic benefit through reduction in infarct size, risk of reinfarction, and mortality.2 …
J. N Khan, A. Chauhan
openaire   +1 more source

Second- and Third-Line Treatment

2019
Sunitinib (sunitinib malate; SU11248) is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. Sunitinib has been identified as a potent inhibitor of VEGFR-1, VEGFR-2, fetal liver tyrosine kinase receptor 3 (FLT3), KIT (stem-cell factor [SCF] receptor), PDGFRα, and PDGFR.
openaire   +1 more source

Second-Line Endocrine Treatment

1988
It was a milestone of cancer therapy in general when Huggins et al. [1] in 1941 first reported the beneficial clinical effects of bilateral orchiectomy in patients with prostate cancer, and the use of castration or estrogens as standard therapy remained the first- line treatment for many years.
openaire   +1 more source

Cabozantinib as a second-line treatment option in hepatocellular carcinoma

Expert Review of Clinical Pharmacology, 2020
Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor tyrosine kinases approved for renal cell carcinoma that could be useful also for the treatment of HCC.This review describes the chemical structure ...
D'Angelo, Alberto, Sobhani, Navid, Bagby, Stefan, Casadei-Gardini, Andrea, Roviello, Giandomenico   +4 more
openaire   +4 more sources

Second-line treatments of small-cell lung cancers

Expert Review of Anticancer Therapy, 2017
Second-line therapies for relapsed small cell lung cancer (SCLC) patients remain a challenge, with limited clinical benefit because of rapid tumor growth, early dissemination and the development of drug resistance during the disease. Recent developments in genomic sequencing have provided further insight into the biology of the disease, identifying new
Nathalie, Baize, Isabelle, Monnet, Laurent, Greillier, Gilles, Quere, Mallorie, Kerjouan, Henri, Janicot, Alain, Vergnenegre, Jean Bernard, Auliac, Christos, Chouaid   +8 more
openaire   +2 more sources

Second-line treatment of small-cell lung cancer

Current Oncology Reports, 2006
Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the majority of patients will ultimately relapse. Therefore, active second-line therapy is needed for this patient population.
Cecilia, MacCallum, Heidi H, Gillenwater
openaire   +2 more sources